AI-based drug discovery: Chemical vs. drugs (Part 4)
This newsletter is part of a series — here are the links to Part 1, Part 2, Part 3, (this one is Part 4), and Part 5. You might also
30 May 2023
No Comments
R&D Insight
Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin
This newsletter is part of a series — here are the links to Part 1, (this one is Part 2), Part 3, Part 4, and Part 5. Also relevant
24 February 2020
No Comments
Chemicals vs. drugs (Part 1): The end of bacitracin / the buzz around halicin
This newsletter is the first of a series — here are the links to Part 2, Part 3, Part 4, and Part 5. You might also
21 February 2020
No Comments
CDC: Funding opportunities (1 each) in US, Africa, and Asia
Dear All: CDC have recently posted this eclectic mixture of funding opportunities that circle the globe! Funding opportunity: CDC-RFA-CK-26-0107 Title: “Building National Partnerships for the
2 June 2026
No Comments
PACCARB returns! 16 June 2026 virtual meeting
Dear All: Without much fanfare, we have an announcement that PACCARB (the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) is being revived at a
30 May 2026
No Comments
EUR 20m funding for next-gen diagnostics for LRTIs (Novo Nordisk Foundation)
Dear All: I have just learned of a recently opened grant program from NNF (Novo Nordisk Foundation) that seeks to fund early-stage proof-of-concept on rapid,
28 May 2026
No Comments
Great AMR-focused podcast series on BBC Discovery!
Dear All, The BBC’s Roland Pease has put together a 3-part podcast series on AMR! Each episode is about 30 minutes, perfect for bite-sized listening.
6 April 2026
No Comments
WHO: New TPPs for antibacterial agents
Dear All, You may recall that in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A description of the desired attributes
23 March 2026
No Comments
Economic modeling of the value of rapid diagnostics
Dear All (and again with thanks to Arjun Srinivasan for co-authoring this pair of newsletters): In parallel with the newsletter discussing a recent paper on
27 May 2026
No Comments
BARDA seeks info on Phase 2+ antifungals for Candida and Aspergillus
Dear All: As discussed in prior newsletters, BARDA is constantly working to ensure it has adequate medical countermeasures (MCMs) for a variety of possible threats.
22 May 2026
No Comments